Correlation Between Karyopharm Therapeutics and Inhibrx

Can any of the company-specific risk be diversified away by investing in both Karyopharm Therapeutics and Inhibrx at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Karyopharm Therapeutics and Inhibrx into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Karyopharm Therapeutics and Inhibrx, you can compare the effects of market volatilities on Karyopharm Therapeutics and Inhibrx and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Karyopharm Therapeutics with a short position of Inhibrx. Check out your portfolio center. Please also check ongoing floating volatility patterns of Karyopharm Therapeutics and Inhibrx.

Diversification Opportunities for Karyopharm Therapeutics and Inhibrx

0.53

Correlation Coefficient

Karyopharm Therapeutics  Inhibrx

Very weak diversification

The 3 months correlation between Karyopharm and Inhibrx is 0.53. Overlapping area represents the amount of risk that can be diversified away by holding Karyopharm Therapeutics and Inhibrx in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Inhibrx and Karyopharm Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Karyopharm Therapeutics are associated (or correlated) with Inhibrx. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Inhibrx has no effect on the direction of Karyopharm Therapeutics i.e., Karyopharm Therapeutics and Inhibrx go up and down completely randomly.

Pair Corralation between Karyopharm Therapeutics and Inhibrx

Given the investment horizon of 90 days Karyopharm Therapeutics is expected to under-perform the Inhibrx. In addition to that, Karyopharm Therapeutics is 1.91 times more volatile than Inhibrx. It trades about -0.03 of its total potential returns per unit of risk. Inhibrx is currently generating about -0.02 per unit of volatility. If you would invest  1,533  in Inhibrx on September 26, 2024 and sell it today you would lose (84.00) from holding Inhibrx or give up 5.48% of portfolio value over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Weak
Accuracy	100.0%
Values	Daily Returns

Karyopharm Therapeutics  vs.  Inhibrx

Karyopharm Therapeutics

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Karyopharm Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. Despite latest weak performance, the Stock's basic indicators remain strong and the recent confusion on Wall Street may also be a sign of long-lasting gains for the firm traders.

Inhibrx

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Inhibrx has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of fairly strong fundamental drivers, Inhibrx is not utilizing all of its potentials. The latest stock price disturbance, may contribute to short-term losses for the investors.

Pair Trading with Karyopharm Therapeutics and Inhibrx

The main advantage of trading using opposite Karyopharm Therapeutics and Inhibrx positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Karyopharm Therapeutics position performs unexpectedly, Inhibrx can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Inhibrx will offset losses from the drop in Inhibrx's long position.

The idea behind Karyopharm Therapeutics and Inhibrx pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Correlation Analysis module to reduce portfolio risk simply by holding instruments which are not perfectly correlated.